Clinical Trial

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Study acronym: RESILIENT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo.
Protocol Amendment History 1 change
minor Completion pushed: 2026-06 -> 2027-12 2026-06-02
Trial Details
NCT Number NCT05337553
Lead Sponsor Biohaven Pharmaceuticals, Inc.
Conditions Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Enrollment 269 participants
Start Date 2022-07-06
Primary Completion 2024-09-25 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-01